The findings question the "more is better" mantra for preventing MRSA.
CARB-X said today it has awarded Lytica Therapeutics, of Cambridge, Massachusetts, up to $5.3 million to develop antibacterial peptides that have broad activity against multidrug-resistant bacteria for treating lung and other infections.
All three confirmed Ebola cases reported in the past week in the Democratic Republic of the Congo (DRC) involved known transmission chains, which is a good sign, but volatile situations still plague the outbreak region, the World Health Organization (WHO) said yesterday in its weekly situation report.
Hong Kong, meanwhile, reports a respirator shortage.
The CDC issues a watch but does not call for travel limits.
The outbreak raises questions about not only the pathogen, but how patients were exposed.
Local sources say the market linked to the cases sold some live animals and animal organs, raising concerns about zoonotic virus spread.
Health officials in China are investigating the cause of a pneumonia outbreak in the city of Wuhan in Hubei province that has sickened 27 people and seems to be linked to a seafood market.
The US Food and Drug Administration (FDA) today approved a new test to diagnose methicillin-resistant Staphylococcus aureus (MRSA), which will allow health workers to screen patients for MRSA colonization more quickly—in as little as 5 hours compared with 24 to 48 hours for traditional culture-based tests.
Rapid, biomarker-guided tests did not help cut antibiotic use in ICU patients.